LAGEVRIO
Generic: molnupiravir
- Manufacturer
- Merck
- NDC
- 0006-5055
- RxCUI
- 2587906
- Route
- ORAL
- ICD-10 indication
- U07.1
Affordability Check
How much will you actually pay for LAGEVRIO?
In 30 seconds, see every legitimate way to afford LAGEVRIO — Medicare copay, manufacturer copay card, Patient Assistance Program, grants, or cash.
About LAGEVRIO
What is this medication?
Lagevrio, also known by its generic name molnupiravir, is an oral antiviral medication used to treat mild-to-moderate COVID-19 in adults. It is specifically intended for individuals who have tested positive for the SARS-CoV-2 virus and are at a high risk of developing severe illness, which could lead to hospitalization or death. This medication is typically prescribed when other authorized COVID-19 treatment options are either not accessible or are not clinically appropriate for the patient.
The drug works by interfering with the ability of the virus to replicate within the body. By introducing errors into the viral genetic material during the replication process, it helps to lower the viral load and reduce the overall severity of the infection. It is important to note that Lagevrio is not authorized for use in patients under the age of eighteen, nor is it intended for the prevention of COVID-19 or for use in patients already hospitalized due to the virus.
Copay & patient assistance
- Patient Copay Amount: Not Publicly Available
- Maximum Annual Benefit Limit: Not Publicly Available
- Core Eligibility Restrictions: Not Publicly Available
- RxBIN, PCN, and Group numbers: Not Publicly Available
External links go directly to the manufacturer's portal. RxCopays does not receive compensation for referrals.
Compare pricing elsewhere
RxCopays doesn't sell drugs or take referral fees. Here are the transparent-pricing directories we recommend checking alongside your insurance formulary.
Cost Plus Drug Company
Mark Cuban's transparent-pricing pharmacy — manufacturer cost + 15% markup + $5 dispensing fee. No insurance needed. Search alphabetically for molnupiravir.
Browse Cost Plus medications →
GoodRx
Compare local pharmacy prices with GoodRx coupons. Use the price with your insurance or without — whichever is cheaper.
Lookup LAGEVRIO →
NeedyMeds
Independent nonprofit directory of patient assistance programs, copay cards, and charity co-pay foundations.
Search for molnupiravir →
RxAssist
PAP directory maintained by Volunteers in Health Care at Brown University. Free, no ads.
Search PAPs →
We deep-link because transparency helps patients. None of these partners pay RxCopays.
Conditions we've indexed resources for
Click a condition to see copay cards, grants, and PA rules specific to it. For the full list of FDA-approved indications, see Prescribing information above.
Medicare Part D coverage
How LAGEVRIO appears across Medicare Part D plan formularies nationally. Source: CMS monthly Prescription Drug Plan file (2026-07-31).
Covered by plans
28%
1,510 of 5,490 plans
Most common tier
Tier 3
On 49% of covering formularies
Prior authorization required
0%
of covering formularies
| Tier | Formularies on this tier | Share |
|---|---|---|
| Tier 1 (preferred generic) | 23 | 23% |
| Tier 2 (generic) | 13 | 13% |
| Tier 3 (preferred brand) | 49 | 49% |
| Tier 4 (non-preferred brand) | 9 | 9% |
| Tier 5 (specialty) | 5 | 5% |
Step therapy: 0% of formularies
Quantity limits: 88% of formularies
Coverage breadth: 99 of 65 formularies
How to read this:plans on the same formulary share tier + PA rules. Your specific plan's copay depends on (a) the tier above, (b) your plan's cost-share for that tier, (c) whether you're in the initial coverage phase or past the 2026 $2,000 out-of-pocket cap. For your exact plan, check its Summary of Benefits or log in to your Medicare.gov account. Copay cards don't apply to Medicare (federal law).
Prior authorization & coverage
| Payer | PA | Step therapy | Copay tier |
|---|---|---|---|
— Medicare Part D | — | — | — |
Related drugs
Veklury
Treats same condition · remdesivir
AVTOZMA
Treats same condition · tocilizumab
Paxlovid
Treats same condition · nirmatrelvir and ritonavir
Tocilizumab-anoh
Treats same condition · tocilizumab
TYENNE
Treats same condition · Tocilizumab-aazg
Olumiant
Treats same condition · baricitinib
TOFIDENCE
Treats same condition · Tocilizumab
WINREVAIR
Also from Merck · SOTATERCEPT-CSRK
Cyclobenzaprine Hydrochloride
Also from Merck · CYCLOBENZAPRINE HYDROCHLORIDE
STEGLUJAN
Also from Merck · ertugliflozin and sitagliptin
How this page is sourced
- Drug identity verified against openFDA NDC Directory.
- Label text (when shown) originates from NLM DailyMed.
- Copay and assistance URLs verified periodically; if you hit a broken link, tell us.